You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Non-invasive method to evaluate the quality of human oocytes and embryos

    SBC: Renova Life Inc.            Topic: NICHD

    DESCRIPTION (provided by applicant): Project Summary We propose to develop a non-invasive method to predict mammalian oocyte quality by analyzing the surrounding cumulus cells' gene expression patterns (cGEP). The result of the cGEP assay---a cGEP score---can be used to predict embryo quality and ultimately the embryo transfer (ET) results. This technology, if success, will for the first time ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Noninvasive Monitoring of Total Hemoglobin Concentration in Neonates

    SBC: NONINVASIX INC            Topic: NICHD

    AbstractIn newborn infants intermittent total hemoglobin concentrationTHbmeasurement represents an essential diagnostic testHoweverblood sampling in neonates results in iatrogenic anemiais a painful experience for infantsand is a tedious procedure for health care personnelBlood sampling forTHbmeasurements represents a high proportion of painful procedures required in infantsyet heel sticksthe most ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Noninvasive, Optoacoustic Monitoring of Cerebral Circulation in Preterm Neonates

    SBC: NONINVASIX INC            Topic: NICHD

    DESCRIPTION (provided by applicant): Premature, very-low-birth-weight (VLBW; d1500 g) and low-birth-weight (LBW; 1500-2499 g) infants are at increased risk for long-term encephalopathy. 25-50% of the 63,000 VLBW infants born annually in the U.S. have majorlong-term cognitive or neurobehavioral deficits. Postnatal cerebral ischemia appears to play an important role in long-term cognitive sequelae. ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Noninvasive placement and activation of deep-brain stimulating magnetic particles for reduction of drug-seeking behaviors

    SBC: WEINBERG MEDICAL PHYSICS, INC.            Topic: NIDA

    Abstract Deep brain stimulationDBSwith implantable electrodes has been used for reduction of ethanol abuse and drug seeking behaviors in EuropeThe use of such deep brain stimulation procedures has been problematic because of concerns about invasiveness of the procedureApplicant has developed a new noninvasive method of transporting magnetic particles directly to target sites within the brainWe pro ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Non-Metal PN Scavenger/Decomposition Catalysts for Treatment of Migraine

    SBC: CERSCI THERAPEUTICS INCORPORATED            Topic: 102

    Project SummaryAbstract The World Health Organization ranks migraine as therd most prevalent disease worldwide andth most disablingth most in womenmaking it the most common neurological disorderOne of the primary reasons for the disabling nature of migraine is the poor efficacy of currently available therapeuticsLess thanof patients achieve complete relief with acute agents such as triptans and on ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Immuno-oncology Strategy for Targeted Cytotoxic Lymphocyte Activation

    SBC: Courier Therapeutics Inc            Topic: 102

    PROJECT SUMMARY ABSTRACT Systemic administration of high dose ILhas been used since thes as an FDA approved immunotherapy for metastatic cancerDespite the fact that up toof patients treated with high dose ILachieve a durablelong term responsethis therapy is rarely used today due to significant life threatening complicationsSuch complications occur due to ILactivation of vascular endotheliumresulti ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Novel RTL treatment to promote brain repair and cognitive recovery following meth

    SBC: VIROGENOMICS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Methamphetamine (MA) dependence is associated with neuropsychiatric side effects that make the addiction extremely challenging to treat. Patients seeking treatment experience ongoing impairments in cognition, mood, and motivation. Currently, there are no FDA-approved pharmacotherapies for MA dependence. The goal of this proof-of-concept research project is test ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Novel treatment for DIC

    SBC: A2 Therapeutics Inc.            Topic: NHLBI

    Project Summary Several diseasesincluding endotoxemiaand sepsis can cause disseminated intravascular coagulationDICDIC can induce the formation of microvascular thrombicausing organ failure and death in the absence of the appropriate treatmentTo datethere are no drugs to treat DICand several reagents have been tested buttheir strong doses can lead to severe bleedingsignificantly diminishing their ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Numeric Expansion of CD-19 Specific T cells in Magnetic 3D Culture

    SBC: CHEMOSEN3D INC            Topic: NIAID

    Project Summary Adoptive immunotherapy trials using genetically modified natural killerNKand T cells with redirected specificity against B cell malignancies have demonstrated therapeutic efficacyTwo early phase clinical trials have been initiated at The University of Texas MDAnderson Cancer Center to evaluate the safety and efficacy of adoptive transfer of autologous and allogeneic T cells express ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Overcoming anti-PD-1 resistance by systemic delivery of an oncolytic adenovirus that targets TGF-beta

    SBC: Multivir Inc.            Topic: 102

    Project Summary The overall goal of this proposal is to test a novel systemic Adenoviral therapy that targets transforming growth factorTGFand reverses anti PDresistance to treat advanced breast and lung cancersThis STTR grant application illustrates the synergistic relationship between DrPrem Sethinventor of a novel TGFdecoyand MultiVir Inca leader in clinical development of gene based therapeuti ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government